MX387666B - Composiciones y su uso en el tratamiento de citomegalovirus - Google Patents

Composiciones y su uso en el tratamiento de citomegalovirus

Info

Publication number
MX387666B
MX387666B MX2017017128A MX2017017128A MX387666B MX 387666 B MX387666 B MX 387666B MX 2017017128 A MX2017017128 A MX 2017017128A MX 2017017128 A MX2017017128 A MX 2017017128A MX 387666 B MX387666 B MX 387666B
Authority
MX
Mexico
Prior art keywords
compositions
hcmv
envelope glycoproteins
methods
virus
Prior art date
Application number
MX2017017128A
Other languages
English (en)
Inventor
Anne- Catherine Fluckiger
Charlotte Fribert
David Klatzmann
David E Anderson
Original Assignee
Variation Biotechnologies Inc
Univ Sorbonne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Variation Biotechnologies Inc, Univ Sorbonne filed Critical Variation Biotechnologies Inc
Publication of MX387666B publication Critical patent/MX387666B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20245—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Lubricants (AREA)

Abstract

La presente invención se refiere a composiciones y métodos útiles para tratar la infección por HCMV. Como se describen en la presente las composiciones y métodos se basan en el desarrollo de composiciones inmunogénicas que incluyen partículas tipo virus (VLPs) que comprenden una o más proteínas núcleo del virus de leucemia murina Moloney (MMLV) e incluyen uno o más epítopes de HCMV, tales como, por ejemplo, de las glicoproteínas gB y/o gH de envoltura de HCMV y/o la proteína pp65 de tegumento. Entre otras cosas, la presente invención abarca el reconocimiento de que la combinación de antígenos (e.g., glicoproteínas de envoltura y proteínas estructurales) puede conducir a respuestas inmunes benéficas, por ejemplo, que incluyen tanto una respuesta humoral (e.g., la producción de anticuerpos neutralizantes) como una respuesta celular (e.g., la activación de la célula T).
MX2017017128A 2011-11-11 2012-11-09 Composiciones y su uso en el tratamiento de citomegalovirus MX387666B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161558800P 2011-11-11 2011-11-11
US201261654157P 2012-06-01 2012-06-01
PCT/IB2012/002854 WO2013068847A2 (en) 2011-11-11 2012-11-09 Compositions and methods for treatment of cytomegalovirus

Publications (1)

Publication Number Publication Date
MX387666B true MX387666B (es) 2025-03-18

Family

ID=48290708

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017017128A MX387666B (es) 2011-11-11 2012-11-09 Composiciones y su uso en el tratamiento de citomegalovirus
MX2014005653A MX353189B (es) 2011-11-11 2012-11-09 Composiciones y su uso en el tratamiento de citomegalovirus.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014005653A MX353189B (es) 2011-11-11 2012-11-09 Composiciones y su uso en el tratamiento de citomegalovirus.

Country Status (14)

Country Link
US (3) US9777043B2 (es)
EP (2) EP2776567B1 (es)
JP (2) JP6232544B2 (es)
KR (2) KR102301463B1 (es)
CN (3) CN107875382B (es)
AU (3) AU2012335277B2 (es)
BR (2) BR112014011229B1 (es)
CA (2) CA3166278A1 (es)
DK (1) DK2776567T3 (es)
ES (1) ES2874233T3 (es)
MX (2) MX387666B (es)
PT (1) PT2776567T (es)
RU (2) RU2019139064A (es)
WO (1) WO2013068847A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3330368B1 (en) 2009-06-18 2021-07-21 Kiyatec Inc. Bioreactor system
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS63430B1 (sr) 2010-10-01 2022-08-31 Modernatx Inc Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK3682905T3 (da) 2011-10-03 2022-02-28 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf
US9777043B2 (en) 2011-11-11 2017-10-03 Variation Biotechnologies Inc. Compositions and methods for treatment of cytomegalovirus
DE12858350T1 (de) 2011-12-16 2021-10-07 Modernatx, Inc. Modifizierte mrna zusammensetzungen
CA2867789C (en) 2012-03-27 2022-06-14 Variation Biotechnologies Inc. Methods for detection of anti-cytomegalovirus neutralizing antibodies
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
HK1206601A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP2914284B1 (en) * 2012-10-30 2016-09-21 Pfizer Inc. Recombinant particle based vaccines against human cytomegalovirus infection
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015193143A1 (en) 2014-06-18 2015-12-23 Morphosys Ag Fusion proteins and uses thereof
KR101678740B1 (ko) * 2014-10-24 2016-11-23 단국대학교 천안캠퍼스 산학협력단 세포 부착활성 및 골분화 촉진활성을 나타내는 피브로넥틴 융합단백질
US12060391B2 (en) 2015-03-16 2024-08-13 The Broad Institute, Inc. Constructs for continuous monitoring of live cells
WO2017068077A1 (en) 2015-10-20 2017-04-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and products for genetic engineering
CA3002922A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
WO2017162265A1 (en) * 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
WO2018075980A1 (en) 2016-10-21 2018-04-26 Modernatx, Inc. Human cytomegalovirus vaccine
WO2018165631A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Cancer vaccine
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
EP3784276A4 (en) * 2018-04-24 2022-03-16 Merck Sharp & Dohme Corp. SCALABLE CHROMATOGRAPHY PROCEDURE FOR PURIFICATION OF HUMAN CYTOMEGALOVIRUS
KR20210013571A (ko) 2018-05-04 2021-02-04 스파이바이오테크 리미티드 백신 조성물
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
BR112021024157A2 (pt) * 2019-05-31 2022-04-26 Variation Biotechnologies Inc Composições imunoterapêuticas para tratamento de glioblastoma multiforme
JP2022536364A (ja) 2019-06-13 2022-08-15 ザ ジェネラル ホスピタル コーポレイション 操作されたヒト内在性ウイルス様粒子および細胞への送達のためのその使用方法
GB201910651D0 (en) * 2019-07-25 2019-09-11 Autolus Ltd Virus-like particle
WO2021048081A1 (en) 2019-09-09 2021-03-18 Glaxosmithkline Biologicals Sa Immunotherapeutic compositions
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide
WO2022020800A2 (en) 2020-07-24 2022-01-27 The General Hospital Corporation Enhanced virus-like particles and methods of use thereof for delivery to cells
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
CN115948468A (zh) * 2022-09-09 2023-04-11 青岛大学 一种人巨细胞病毒重组载体及其制备方法和应用
WO2024243675A1 (en) * 2023-06-02 2024-12-05 Variation Biotechnologies Inc. Compositions of mrna-encoded virus-like particles, compositions of mrna-lipid nanoparticles, and methods for use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267965B1 (en) 1981-12-24 2001-07-31 Virogenetics Corporation Recombinant poxvirus—cytomegalovirus compositions and uses
JPS61103895A (ja) * 1984-10-26 1986-05-22 Green Cross Corp:The ＨＢｓＡｇの精製方法
DE68929478T2 (de) * 1988-01-29 2004-04-29 Aventis Pasteur Rekombinante CMV-Neutralisierungsproteine
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
DE19856463B4 (de) * 1998-11-26 2006-02-02 Heinrich-Pette-Institut Retrovirale, mit LCMV pseudotypisierte Hybrid-Vektoren
DE19910044A1 (de) 1999-03-08 2000-09-14 Bodo Plachter Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
JP2003512305A (ja) 1999-09-30 2003-04-02 ユニバーシティ オブ ワシントン 免疫学的に重要な単純疱疹ウイルス抗原
EP1201750A1 (en) * 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
US9045727B2 (en) * 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
WO2004058166A2 (en) 2002-12-23 2004-07-15 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
US7419674B2 (en) 2003-07-11 2008-09-02 Alpha Vax, Inc. Alpha virus-based cytomegalovirus vaccines
RU2290204C1 (ru) * 2005-07-27 2006-12-27 Общество с ограниченной ответственностью "Аванген" Рекомбинантный гибридный белок, препарат для иммунотерапии на его основе и способ иммунотерапии рецидивирующего папилломатоза гортани
JP2009544322A (ja) 2006-07-27 2009-12-17 リゴサイト ファーマシューティカルズ インコーポレイテッド キメラウイルス様粒子
US20090123494A1 (en) 2007-07-31 2009-05-14 William Staplin Momlv-based pseudovirion packaging cell line
US20110250675A1 (en) 2008-03-26 2011-10-13 Life Technologies Corporaiton Virus-Like Particle Mediated Cellular Delivery
GB0907935D0 (en) * 2009-05-08 2009-06-24 Henderson Morley Plc Vaccines
US9777043B2 (en) 2011-11-11 2017-10-03 Variation Biotechnologies Inc. Compositions and methods for treatment of cytomegalovirus
CN106102769A (zh) * 2013-12-11 2016-11-09 促进军事医学的亨利·M·杰克逊基金会公司 人疱疹病毒三聚糖蛋白B、包含三聚gB的蛋白复合体及其作为疫苗的用途

Also Published As

Publication number Publication date
CN111995664A (zh) 2020-11-27
EP2776567A4 (en) 2015-12-30
US20230272013A1 (en) 2023-08-31
CA3166278A1 (en) 2013-05-16
CN107875382A (zh) 2018-04-06
EP2776567B1 (en) 2021-01-20
PT2776567T (pt) 2021-05-25
KR102340558B1 (ko) 2021-12-21
EP3854416A1 (en) 2021-07-28
US12421283B2 (en) 2025-09-23
ES2874233T3 (es) 2021-11-04
RU2737530C1 (ru) 2020-12-03
AU2012335277B2 (en) 2018-06-14
AU2012335277A1 (en) 2014-06-12
AU2018203538A1 (en) 2018-06-07
BR122019027913B1 (pt) 2021-11-30
JP2015505299A (ja) 2015-02-19
DK2776567T3 (da) 2021-04-26
RU2019139064A (ru) 2020-01-27
KR102301463B1 (ko) 2021-09-14
CA2889659C (en) 2023-03-14
CN104271745A (zh) 2015-01-07
JP2018023374A (ja) 2018-02-15
WO2013068847A3 (en) 2014-10-30
US20140308308A1 (en) 2014-10-16
CA2889659A1 (en) 2013-05-16
WO2013068847A2 (en) 2013-05-16
CN107875382B (zh) 2024-03-08
KR20190104644A (ko) 2019-09-10
BR112014011229A2 (pt) 2017-05-09
US9777043B2 (en) 2017-10-03
MX2014005653A (es) 2014-09-04
US20170349634A1 (en) 2017-12-07
JP6657150B2 (ja) 2020-03-04
KR20140095556A (ko) 2014-08-01
EP2776567A2 (en) 2014-09-17
BR112014011229B1 (pt) 2021-10-13
CN111995664B (zh) 2024-08-02
AU2020264275A1 (en) 2020-11-26
MX353189B (es) 2018-01-05
US11248026B2 (en) 2022-02-15
AU2020264275B2 (en) 2023-12-14
JP6232544B2 (ja) 2017-11-22

Similar Documents

Publication Publication Date Title
MX387666B (es) Composiciones y su uso en el tratamiento de citomegalovirus
PH12017500727A1 (en) Modified virus-like particles of cmv
ZA201807467B (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
CY1119284T1 (el) ΣΩΜΑΤΙΔΙΑ ΠΑΡΟΜΟΙΑ ΜΕ ΙΟ ΓΛΥΚΟ-ΠΡΩΤΕΪΝΗΣ ΛΥΣΣΑΣ (VLPs)
EA201391170A1 (ru) Терапевтическое средство на основе дрожжей для лечения хронического гепатита b
MX2014000749A (es) Anticuerpos neutralizantes del virus de la influenza a y usos de estos.
MX2015008847A (es) Composiciones inmunogenicas de virus de influenza y usos de las mismas.
MY187161A (en) Antibodies that potently neutralize hepatitis b virus and uses thereof
EA201391713A1 (ru) Нейтрализующие вирус иммунодефицита человека антитела и способы их применения
EP2765138A3 (en) HIV-1 envelope glycoprotein
EA201391515A1 (ru) Инактивированная вакцина вируса денге
EP4043031A3 (en) Zika viral antigen constructs
NZ741875A (en) Canine parvovirus (cpv) virus-like particle (vlp) vaccines and uses thereof
PH12021550521A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
EA201790680A1 (ru) Вакцины против вируса иммунодефицита человека (вич), содержащие один или более эписенсусных (episensus) для популяции антигенов
WO2014128568A3 (en) Compositions and methods for treatment of hepatitis c
EP2873423A3 (en) Soluble hiv-1 envelope glycoprotein trimers
EA201291437A1 (ru) Концентрация вакцинных антигенов без лиофилизации
EA201400216A1 (ru) Консервирование биологических продуктов, в частности вакцин, с применением вакуума
WO2014043220A3 (en) Hiv-1 envelope proteins and fragments thereof that possess epitopes recognized by broadly neutralizing antibodies
WO2017053525A3 (en) Influenza vaccine and therapy
WO2016075546A3 (en) Antibodies that neutralize ebola virus and uses thereof
MX2019007924A (es) Vacunas contra la influenza.
WO2013026452A9 (en) Method for removing immunosuppresive properties of hiv envelope glycoproteins
EA201890187A1 (ru) Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита